Type 2 & other diabetes

Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS cardiovascular (CV) , a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin

Diabetes Obes MetabPublished Post hoc analysis of the VERTIS CV randomised trial

Authors' conclusion

In VERTIS CV, higher FIB-4 score was associated with CV events. HSI correlated with HHF. Neither measure was associated with the composite kidney outcome. Ertugliflozin was associated with a reduction in liver enzymes and HSI.

Study context

Population
Patients with T2D and atherosclerotic CVD randomised to ertugliflozin or placebo; mean age 64.4 years, BMI 32.0 kg/m², hepatic steatosis index (HSI) 44.0, FIB-4 1.34
Participants
8,246 patients
Comparison
Highest vs lowest baseline FIB-4 and HSI quartiles
Primary endpoint
Cardiorenal outcomes (MACE; HHF/CV death; CV death; HHF; composite kidney outcome) by baseline HSI and FIB-4 quartiles
Methodological detailspooled ertugliflozin and placebo data, intention-to-treat analysis set
  • Pooled ertugliflozin and placebo data
  • Intention-to-treat analysis set

Primary result

As reported in the abstract

Cardiorenal outcomes by FIB-4 quartile
Q4 vs Q1Hazard ratio (95% CI)P value
MACE, FIB-4
1.48(1.25–1.76)
P < 0.0001 for all
HHF/CV death, FIB-4
2.0(1.63–2.51)
P < 0.0001 for all
CV death, FIB-4
1.85(1.45–2.36)
P < 0.0001 for all
HHF, FIB-4
2.94(1.98–4.37)
P < 0.0001 for all
HHF, HSI; higher in Q4
1.52(1.07–2.17)
P < 0.05

Further findings

Liver enzymes and HSI over time (ertugliflozin vs placebo)

Liver enzymes and HSI decreased over time with ertugliflozin

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV , a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin. Diabetes Obes Metab. Published 26 December 2022. doi:10.1111/dom.14923

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.